Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

The Liposome Co. Inc.


Liposome Technology Inc.


NeXstar Inc.


Based on a comparison of the three companies' lipid-based amphotericin B products to treat fungal infections, UBS Securities analyst Marc Ostro said that he expects LIPO's

Read the full 388 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers